论文部分内容阅读
目的探讨经尿道膀胱肿瘤电切术(TURBT)后24h内与2周内吡柔比星(THP)膀胱灌注疗效的比较。方法120例TURBT术后浅表性膀胱移行细胞癌(T1-2,G1-3)患者,按1:1分为A、B两组。分别从术后24h内和2周内开始第1次灌注,均每周一次,共8次,以后每月1次,共1年。每隔3个月膀胱镜检1次,定期复查肝、肾功能,血、尿常规。结果随访4～30个月,平均19个月。A组复发率11.7%(7例),B组复发率21.7%(13例),A组疗效优于B组,具有统计学意义(P<0.05)。结论TUBBT术后24h内与术后2周内开始THP膀胱灌注相比,可以更有效地减少膀胱肿瘤复发。
Objective To investigate the efficacy of intravesical instillation of pirarubicin (THP) within 24 hours and 24 hours after transurethral resection of bladder tumor (TURBT). Methods One hundred and twenty patients with superficial bladder transitional cell carcinoma (T1-2, G1-3) after TURBT were divided into two groups according to 1: 1. The first perfusion was performed within 24 h and within 2 weeks respectively, all once a week for 8 times and once a month for a total of 1 year. Cystoscopy every 3 months 1, regular review of liver and kidney function, blood, urine routine. The results were followed up for 4 to 30 months, an average of 19 months. The recurrence rate was 11.7% (7 cases) in group A and 21.7% (13 cases) in group B, and the effect in group A was better than that in group B (P <0.05). Conclusions TUBBT can reduce the recurrence of bladder tumor more effectively than 24h after TUBBT intravesical instillation within 2 weeks after operation.